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Abstract
Background: Reliable, inexpensive, high-throughput genotyping methods are required for clinical trials. Traditional
assays require numerous enzyme digestions or are too expensive for large sample volumes. Our objective was to
develop an inexpensive, efficient, and reliable assay for CYP2D6 and ADRB1 accounting for numerous polymorphisms
including gene duplications.
Materials and methods: We utilized the multiplex SNaPshot® custom genotype method to genotype CYP2D6 and
ADRB1. We compared the method to reference standards genotyped using the Taqman Copy Number Variant Assay
followed by pyrosequencing quantification and determined assigned genotype concordance.
Results: We genotyped 119 subjects. Seven (5.9 %) were found to be CYP2D6 poor metabolizers (PMs), 18 (15.1 %)
intermediate metabolizers (IMs), 89 (74.8 %) extensive metabolizers (EMs), and 5 (4.2 %) ultra-rapid metabolizers (UMs).
We genotyped two variants in the β1-adrenoreceptor, rs1801253 (Gly389Arg) and rs1801252 (Ser49Gly). The Gly389Arg
genotype is Gly/Gly 18 (15.1 %), Gly/Arg 58 (48.7 %), and Arg/Arg 43 (36.1 %). The Ser49Gly genotype is Ser/Ser 82
(68.9 %), Ser/Gly 32 (26.9), and Gly/Gly 5 (4.2 %). The multiplex SNaPshot method was concordant with genotypes in
reference samples.
Conclusions: The multiplex SNaPshot method allows for specific and accurate detection of CYP2D6 genotypes and
ADRB1 genotypes and haplotypes. This platform is simple and efficient and suited for high throughput.
Keywords: ADRB1, CYP2D6, Copy number variation, Gene deletion, Genotyping, Personalized medicine, Precision medicine
Background
Cytochrome P450 family 2 subfamily D member 6
(CYP2D6) is one of the most important drug-metabolizing
enzymes expressed in humans. The enzyme metabolizes
20–30 % of all xenobiotics including numerous antide-
pressants, antipsychotics, anti-emetics, analgesics, and
cardiovascular medications. The expression of CYP2D6 is
highly polymorphic; more than 70 allelic variants have
been identified, and deletion or duplication of the
gene leads to variable enzyme function in individual
patients [1, 2]. The CYP2D6 gene has been mapped
to chromosome 22q13.1 and consists of nine exons
with an open reading frame of 1491 base pairs coding
for 497 amino acids [2–5]. Variability in enzyme expres-
sion has been associated with altered drug effectiveness
and safety [2]. In fact, there are four functional genotype
groups identified for the enzyme, poor metabolizers
(PMs), intermediate metabolizers (IMs), extensive meta-
bolizers (EMs), and ultra-rapid metabolizers (UMs) based
upon the number and activity of the gene copies the pa-
tients express (Table 1) [1, 6]. Therefore, many researchers
and clinicians have targeted genotyping CYP2D6 in efforts
to improve drug therapy.
Expanding on previously published work [7–9], we
sought to determine the effectiveness and safety of meto-
prolol succinate utilizing a systems biology approach,
whereby we genotyped the drug-metabolizing enzyme
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CYP2D6 as well as the drug target, β1-adrenoreceptor
(ADRB1). Additionally, we captured demographic and
clinical factors that are necessary to understand the poten-
tial for individualized therapy in patients taking metopro-
lol succinate. Metoprolol is a B1 selective antagonist,
known as a beta-blocker. Beta-blockers are first-line
treatment for heart failure, hypertension (HTN), angina,
and myocardial infarction [10–14]. In 2011, 34.5 million
prescriptions for metoprolol were written in the USA [15].
Thus, metoprolol is a first-line therapy for several of the
most common chronic diseases and is one of the most
commonly prescribed drugs in the USA. CYP2D6 is the
only clinically pertinent pathway of metoprolol metabol-
ism, and polymorphisms have been associated with altered
levels of metoprolol [16, 17]. ADRB1 is the drug target,
and polymorphisms in this receptor have been associated
with variable drug response [7, 18]. Prediction of drug
response with knowledge of one without knowledge of the
other could be incomplete since both contribute to the
ultimate clinical effect [19]. This highlights the importance
of accounting for both factors. Prior investigators have
identified imperfect associations with CYP2D6 [16, 17]
and ADRB1 [7, 18] genotypes, but no study has been
appropriately powered to account for variability in both
genotypes [19]. No single assay accounts for variants in
both genes. Given that multiple single-nucleotide variants
(SNVs) and the presence of gene duplication can affect
CYP2D6 and ADRB1, a simple, efficient, and inexpensive
method that identifies both SNVs and gene duplication is
required to allow for an adequately powered systems
biology approach.
CYP2D6 and ADRB1 variants have been identified
using long-range polymerase chain reaction (XL-PCR)
with PCR restriction fragment length polymorphism
(PCR-RFLP) or microarray analysis. Microarray analysis
remains expensive for large-scale genotyping. Commer-
cially available tests cost a minimum of $500 per patient.
XL-PCR with PCR-RFLP accounts for allele variants,
and multiplication is inexpensive, easy, and reliable in
patients regardless of ethnicity or race [6]. However, XL-
PCR with PCR-RFLP requires numerous enzymatic
digestions and multiple amplification steps to identify
more than one polymorphism in the CYP2D6 gene. In
order to conduct a large-scale clinical trial to determine
the effectiveness and safety of metoprolol in treating
hypertension, we sought to develop a simple, rapid, yet
less expensive assay for CYP2D6 and ADRB1 that
accounts for numerous polymorphisms including gene
duplications. Drug effectiveness data will be presented at
a later date when the trial closes.
Material and methods
Study design and setting
This was a prospective observational clinical trial
(NCT02293096) that enrolled patients with uncontrolled
HTN from clinics, the emergency department, and
across the community at the University of Colorado
Hospital in Aurora, Colorado.
Subjects
In accordance with the University of Colorado IRB
approval, we enrolled subjects with uncontrolled HTN
between 30 and 80 years of age. Exclusion criteria
included end-stage liver disease, glomerular filtration
rate < 60 ml/min/1.73 m2, pregnancy, American Society
of Anesthesiologists (ASA) classification of >3, prisoners
or wards of the state, decisionally challenged, heart rate <
60 beats per minute, AV block > 240 ms, active reactive
airway disease, illicit drug use in the preceding 30 days
(excluding marijuana), allergy to metoprolol succinate, or
severe peripheral arterial circulatory disorders.
Drug intervention
Patients were initially managed according to the Eighth
Joint National Committee guidelines for management
of HTN [20]. Patients were started on angiotensin-
converting enzyme inhibitor or angiotensin receptor
blockers as first-line therapy. If blood pressure remained
uncontrolled, then metoprolol succinate was added.
Patients were then followed up and metoprolol titrated
weekly for 4 weeks. Drug effectiveness data will be
presented at a later date.
DNA isolation
Genomic DNA was extracted from whole blood via the
Puregene® Blood Core kit B (Qiagen) according to the
manufacturer’s instructions.
Long-range PCR analyses to determine CYP2D6 gene
multiplication
We analyzed CYP2D6 duplication using long-range PCR
with the primers described by Lovlie et al. [21]. This
primer combination amplifies a 5.2-kb PCR fragment
from the CYP2D7-CYP2D6 intergenic regions in all indi-
viduals and a 3.6-kb PCR fragment from the CYP2D6-
CYP2D6 region in individuals with a duplication of
the gene [22]. The amplification was done using the
Phusion High-Fidelity DNA Polymerase kit (New England
Table 1 Predicted CYP2D6 enzyme function based upon the
activity score derived from SNV identification
Predicted CYP2D6 enzyme function Activity score
Poor metabolizer (PM) 0
Intermediate metabolizer (IM) 0.5
Extensive metabolizer (EM) 1.0–2.0
Ultra-rapid metabolizer (UM) >2.0
Some genes have partial functionality based upon in vitro enzyme activity for
specific substrates. This table is adapted from Crews et al. and Gaedigk et al. [1, 6]
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Biolabs). The reaction components included 2 μl of 5×
Phusion HF buffer, 0.2 μl of 25 mM dNTPs, 0.5 μl of
10 μM/μl forward primer, 0.5 μl of 10 μM/μl reverse pri-
mer, 1 μl of template DNA, 0.2 μl of Phusion DNA poly-
merase, 0.3 μl DMSO, 2.5 μl of BETAIN, and 2.8 μl of
nuclease-free water. The total reaction volume was 10 μl.
Thermal cycling conditions were as follows: 98 °C for 30 s
followed by 35 cycles of 98 °C for 10 s, 67 °C for 30 s, and
72 °C for 2 min 30 s. After cycling, samples were stored at
4 °C. PCR products were analyzed by electrophoresis.
Long-range PCR analyses to determine CYP2D6 gene
deletion
To detect deletion of the entire CYP2D6 gene, (CYP2D6 *5)
we performed a multiplex longer-PCR reaction with the
primers described by Okubo et al. [23]. The reaction com-
ponents included 2 μl of 5× Phusion HF buffer, 0.2 μl of
25 mM dNTPs, 0.2 μl of 10 μM F1 primer, 0.2 μl of 10 μM
R2 primer, 2 μl of 10 μM F3 primer, 1 μl of template DNA,
0.2 μl of Phusion DNA polymerase, 2.5 μl of BETAIN, and
1.7 μl of nuclease-free water. The PCR conditions were as
follows: initiation at 98 °C for 3 min, 35 cycles of 98 °C for
10 s and 70 °C for 30 s, termination at 72 °C for 2 min 30 s,
and a final elongation at 72 °C for 10 min. The PCR prod-
ucts were examined by electrophoresis and include the
amplification of a 3.5-kb fragment, which indicates CYP2D6
*5, and a 4.7-kb fragment, which indicates CYP2D6 wild
type.
SNV selection
We detected 20 variants associated with altered CYP2D6
enzyme activity. SNVs were chosen because they are
representative of major haplotypes associated with al-
tered enzyme function without providing redundancy of
rsIDs leading to the same functional activity within the
same allele variant (Table 2). If none of these SNVs were
identified, the allele designation was defaulted to the ref-
erence allele, CYP2D6*1. Haplotype analysis for CYP2D6
was based upon predicted enzyme activity of the SNVs
identified in the genotyping stage.
Additionally, two ADRB1 SNVs were genotyped (Table 2)
because haplotypes of these alleles are known to be associ-
ated with altered clinical response to metoprolol treatment
(Table 3). If neither of these SNVs were identified, the al-
lele was defaulted to Ser49 and Gly389, the reference
allele.
Genotyping
Genotyping was performed using two separate multiplex
reactions. First, we used PCR to amplify a purified tem-
plate DNA fragment that included the target nucleotide.
We designed a total of eight pairs of PCR primers (Table 4)
that were divided into two separate pools. The PCR
was performed with the AmpliTaq® Gold kit (Applied
Biosystems) using a hot start/touchdown PCR assay. The
10 μl reaction included 1 μl of template DNA, 1.6 μl of
10× GeneAmp® PCR Buffer, 0.15 μl of 25 mM/each
dNTPs, 0.4 μl of 1 μM/each primer mix, 2.15 μl of 50 mM
MgCl2, 0.15 μl of 5 U/μl AmpliTaq Gold, and 4.55 μl of
nuclease-free water. Thermal cycling conditions were as
follows: 94 °C for 5 min followed by 15 cycles of 94 °C for
30 s; annealing temperature steps down every cycle by
Table 2 CYP2D6 and ADRB1 variant alleles with rsIDs and
subsequent effect on the gene sequence
Allele Major nucleotide variation SNV Effect
*1 Presumed NA Wild type
*2 2850C>G rs16947 Arg296Cys
*3 2549delA rs35742686 Frameshift
*4 100C>T rs1065852 Pro34Ser
1846G>A s3892097 Splicing defect
*6 1707delT rs5030655 Frameshift
*7 2935A>C rs5030867 His324Pro
*9 2615_2617delAAG rs5030656 Lys281del
*10 100C>T rs1065852 Pro34Ser
*12 124G>A rs5030862 Gly42Arg
*14 1758G>A rs5030865 Gly169Arg
*17 1023C>T rs28371706 Thr107Ile
2850C>T rs16947 Arg296Cys
*19 2539_2542delAACT rs72549353 255Frameshift
*20 1973_1974insG rs72549354 211Frameshift
*38 2587_2590delGACT rs72549351 271Frameshift
*40 1863_1864insTTTCGCCCCX2 rs72549356 174_175insFRP × 2
*41 2850C>T rs16947 Arg296Cys
2988G>A rs38371725 Splicing defect
*42 3259_3260insGT rs72549346 363Frameshift
*49 100C>T rs1065852 Pro34Ser
1611T>A rs1135822 Phe120Ile
*69 100C>T rs1065852 Pro34Ser
2850C>T rs16947 Arg296Cys







Table 3 ADRB1 haplotype and associated metoprolol clinical effect
ADRB1 haplotypes Metoprolol clinical effect
49Ser389Arg/49Ser389Arg Threefold greater diastolic blood
pressure reduction [7, 12]
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0.5 °C (from 63 to 56.5 °C) every 30 s and then 72 °C for
1 min. The annealing temperature for the final 25 cycles
was 56 °C with a denaturation temperature of 94 °C for
30 s and extension temperature of 72 °C for 1 min. After
PCR, the products were first treated with shrimp alkaline
phosphatase (SAP) and Exonuclease Ι (Exo Ι) to remove
excess primers and dNTPs. Two units of SAP and 1 unit
of Exo Ι were added to 5 μl of PCR product and incubated
at 37 °C for 30 min and then 80 °C for 15 min. Second, we
performed multiplex single-base extraction (SBE) reac-
tions. We designed 19 SBE primers and divided the reac-
tions into two pools. See Table 5. Each SBE reaction was
carried out in a 10 μl final volume containing 5 μl of
SNaPshot Multiplex Ready Reaction Mix, 2 μl of pooled
PCR products, 1 μl of pooled SNaPshot primers (0.3 μmol/
each μl), and 2 μl of deionized water. Extension was per-
formed for 25 cycles under the following conditions: 96 °C
for 10 s, 50 °C for 5 s, and 60 °C for 30 s. To remove
ddNTPs, the SBE reactions were then treated with 1.0 unit
of calf-intestinal phosphatase (CIP) and incubated at 37 °C
for 30 min. The enzyme was deactivated by incubating at
80 °C for 15 min. The samples were run by electrophoresis
on the 3130 Genetic Analyzer (Applied Biosystems). The
subsequent data were analyzed with GeneScan software
and GeneScan-120 LIZ size standard.
CYP2D6 multiple-copy allele determination
The SNaPshot Multiplex System (Applied Biosystems) is
a primer extension-based method developed for the ana-
lysis of SNVs. Theoretically, with the same SNV peak in
the same reacting system with the same reaction condi-
tions, a comparatively higher density means more DNA
copies, and the ratios of any two peak densities of the
same sample are relatively inflexible. We identified the
copy numbers and duplicated/multiplicated allele by the
ratio of the peak densities. In each pool, we designed
one primer to identify an ADRB1 gene’s SNV. ADRB1 is
a single-copy gene which allowed us to use the peaks of
ADRB1 gene’s SNVs as the inner standard peaks. We
calculated the ratios of the peak density of CYP2D6
SNVs to the peak density of the ADRB1 SNV. We set
the reliability value range of the ratios of each SNV
based on the values of the ratio of single-copy control
samples with the same SNVs. If a ratio of a SNV of a
known duplicated sample was greater than the max-
imum of the reference reliability range, this SNV was
Table 4 The oligonucleotide PCR primers used for amplification of genomic DNA to obtain template
Multiplex pool Fragment name Sequence 5′→ 3′ Length (bases) Product size (bp) SNV
1 P1PCR1 agcccggtaacctgtcgt 18 162 rs1801252
ccatcagcagacccatgc 18
P1PCR2 tggaggaggtcaggcttaca 20 342 rs16947
ggtgcagaattggaggtcat 20 rs5030867
rs28371725
P1PCR3 gtgtggtggcattgaggact 20 332 rs72549346
gtggggacgcatgtctgt 18




2 P2PCR1 gccttcaaccccatcatcta 20 328 rs1801253
ggccctacaccttggattc 19
P2PCR2 ctcacctggtcgaagcagta 20 145 rs1065852
ccatcttcctgctcctggt 19 rs5030862
P2PCR3 cagctcggactacggtcatc 20 272 rs28371706
cttgacaagaggccctgacc 20
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Table 5 The oligonucleotide primers for SNaPshot primer extension reactions
Multiplex pool SNV Primer direction Peak to SNV correspondence Primer length Primer sequence (5′→ 3′)
1 rs28371725C/T F(C/T) C=C T=T 16 CCCCGCCTGTACCCTT
rs1801252A/G F(A/G) A=A G=G 18 GACTCTCCCGCCAGCGAA
rs72549346-/AC R(T/G) T=AC C=- 30 GACTGACTGACTGCCGTGATTCATGAGGTG
rs16947A/G F(A/G) A=A G=G 40 GACTGACTGACTGACTGACTGAGGTCAGCCACCACTATGC
rs5030656-/CTT F(T/C) T=CTT C=- 40 GACTGACTGACTGACTGACTGATGGCAGCCACTCTCACCT
rs72549351-/AGTC R(C/G) C=AGTC G=- 46 GACTGACTGACTGACTGACTGACTGACTGACCCCCCCGAGACCTGA
rs72549353-/AGTT F(T/A) T=AGTT A=- 46 GACTGACTGACTGACTGACTGACTGACCAGGTCATCCTGTGCTCAG
rs35742686-/T F(T/G) T=T G=- 52 GACTGACTGACTGACTGACTGACTGACTGACTGACTGGGTCCCAGGTCATCC
rs5030867T/G R(A/C) A=T C=G 52 GACTGACTGACTGACTGACTGACTGACTGACTCCTCCTGCTCATGATCCTAC
2 rs1801253C/G F(C/G) C=C G=G 15 CGCAAGGCCTTCCAG
rs72549356-/
GGGGCGAAAGGGGCGAAA
R(T/A) T=GGGGCGAAAGGGGCGAAA A=- 18 GACTGCCCCTTTCGCCCC
rs1065852G/A R(C/T) C=G T=A 36 GACTGACTGACTGACTGACTCTGGGCTGCACGCTAC
rs3892097T/C R(A/G) A=T G=C 36 GACTGACTGACTGACTGACTGCATCTCCCACCCCCA
rs28371706G/A R(C/T) C=G T=A 43 GACTGACTGACTGACTGACTGACTGACTCGCCTGTGCCCATCA
rs5030862T/C R(A/G) A=T G=C 43 GACTGACTGACTGACTGACTGACTGACTCCCCTGCCACTGCCC
rs72549354-/C F(T/C) T=- C=C 47 GACTGACTGACTGACTGACTGACTGACTCGACTCCTCCTTCAGTCCC
rs5030655-/A R(T/G) T=T G=- 51 GACTGACTGACTGACTGACTGACTGACTGACTCAAGAAGTCGCTGGAGCAG
rs1135822A/T F(A/T) A=A T=T 55 GACTGACTGACTGACTGACTGACTGACTGACTGACTGACTCATAGCGCGCCAGGA














designated a duplication. We identified the copy number
based upon that value. Based on published results and
the values of the ratios, we assume all duplicated sam-
ples have the total copy number of three since this was
the highest number of copy number variants (CNVs) in
our controls.
Activity scoring and predicted phenotype assignment
Each identified CYP2D6 SNV was assigned a predicted
enzyme activity score [1, 6]. Gene deletions were desig-
nated as an activity score of zero. The predicted enzyme
phenotype was determined by addition of the individual
gene activity scores, accounting for gene copies yielding
decreased enzyme activity and gene duplications in each
patient. A score of 0 was predicted to be a PM, 0.5 was
predicted to be IM, 1–2 was predicted to be an EM, and
2.5 or greater was predicted to have a UM phenotype.
Assay verification
Genotypes were confirmed with known reference geno-
type samples from 5 PMs, 4 IMs, and 24 EMs [8, 24].
Copy number variations were determined by Taqman
Copy Number Assay (Life Technologies, CA) and then




The demographics on the initial 79 subjects with un-
known haplotypes in this cohort were as follows: the
median age was 52 (IQR 45, 60), 46 (58.2 %) were males,
14 (19.9 %) were Hispanic/Latino, 37 (46.8 %) were
Black or African American, 3 (3.8 %) were American
Indian or Alaskan Native, 3 (3.8 %) were of Asian de-
cent, 1 (1.3 %) was Native Hawaiian or Pacific Islander,
and 38 (48.1 %) were Caucasian.
Genotypes
Our genotyping method demonstrated consistent results
with all 30 reference standards. The CYP2D6 haplotype
analysis revealed 7 (5.88 %) CYP2D6 PMs, 18 (15.1 %)
IMs, 89 (74.78 %) EMs, and 5 (4.2 %) UMs (Table 6).
We also genotyped two variants of ADRB1, rs1801253
(Gly389Arg) and rs1801252 (Ser49Gly). The Gly389Arg
genotype is Gly/Gly 18 (15.1 %), Gly/Arg 58 (48.7 %),
and Arg/Arg 43 (36.1 %). The Ser49Gly genotype is Ser/
Ser 82 (68.9 %), Ser/Gly 32 (26.9), and Gly/Gly 5 (4.2 %).
See Table 7. CYP2D6 allele frequencies are shown in
Table 8. All genotypes were in the Hardy-Weinberg
equilibrium (HWE) after allele designation by SNV iden-
tification and CNV determination.
Table 6 Distribution of CYP2D6 genotypes and phenotypes











*1/*2xN 1 0.84 3.0 UM 4.2
*1xN/*2 1 0.84 3.0 UM 4.2
*1/*1xN 1 0.84 3.0 UM 4.2
*2/*2xN 1 0.84 3.0 UM 4.2
*1xN/*2 1 0.84 3.0 UM 4.2
*1/*1 15 12.61 2.0 EM 74.8
*1/*2 15 12.61 2.0 EM 74.8
*1/*3 4 3.36 1.0 EM 74.8
*1/*4 7 5.88 1.0 EM 74.8
*1/*6 2 1.68 1.0 EM 74.8
*1/*10 4 3.36 1.5 EM 74.8
*1/*17 8 6.72 1.5 EM 74.8
*1/*41 7 5.88 1.5 EM 74.8
*2/*2 4 3.36 2.0 EM 74.8
*2/*3 1 0.84 1.0 EM 74.8
*2/*4 2 1.68 1.0 EM 74.8
*2/*5 2 1.68 1.0 EM 74.8
*2/*10 2 1.68 1.5 EM 74.8
*2/*17 6 5.04 1.5 EM 74.8
*2/*40 1 0.84 1.0 EM 74.8
*2/*41 3 3.52 1.5 EM 74.8
*17/*17 1 0.84 1.0 EM 74.8
*1/*4xN 1 0.84 1.0 EM 74.8
*2xN/*12 1 0.84 2.0 EM 74.8
*2/*17xN 2 1.68 2.0 EM 74.8
*1/*5 1 0.84 1.0 EM 74.8
*4/*9 1 0.84 0.5 IM 16
*4/*17 2 1.68 0.5 IM 16
*5/*17 2 1.68 0.5 IM 16
*4/*41 4 3.36 0.5 IM 16
*5/*41 2 1.68 0.5 IM 16
*6/*17 1 0.84 0.5 IM 16
*6/*41 1 0.84 0.5 IM 16
*10/*40 1 0.84 0.5 IM 16
*17/*40 2 1.68 0.5 IM 16
*4xN/*10 1 0.84 0.5 IM 16
*4xN/*41 1 0.84 0.5 IM 16
*3/*4 1 0.84 0.0 PM 5.9
*4/*4 4 3.36 0.0 PM 5.9
*4xN/*5 2 1.68 0.0 PM 5.9
PM poor metabolizer, IM intermediate metabolizer, EM extensive metabolizer,
UM ultra-rapid metabolizer
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Copy number variants
We identified 13 subjects with CNVs with predicted
enzyme activities scores ranging from 0 to 3 (Table 9).
An example CNV determination is as follows. One sam-
ple had a genotype of *4/*41 and the total gene copy
number of three. In this sample, we detected four
heterozygous SNVs: rs1065852, rs3892097, rs28371725,
and rs16947. The ratio of rs1065852 was 0.92, higher
than the maximum of the reference reliability range
(0.7–0.85). The ratio of rs3892097 was 0.98, higher than
the maximum of the reference reliability range (0.6–0.9).
The ratio of rs28371725 was 1.97, lower than the mini-
mum of the reference reliability range (2.4–2.9). The
ratio of rs16947 was 1.09, lower than minimum of the
reference reliability range (1.28–1.38). All these ratios
suggest that the variant allele, *4 was duplicated in this
sample. Thus, the genotype is *4xN/*41. Since *4 is a
non-functional allele, the activity score is assigned 0, and
*41 is a reduced function allele, assigned an activity
score of 0.5, even if the *4 is duplicated, the activity
score remains 0.5. Hence, the genotype for this sample
was designated IM (Table 6).
Assay verification
Genotyping results for the UM alleles showed a high
degree of concordance between the Taqman Copy Number
Assay paired with pyrosequencing quantification [24] and
our SNaPshot methods. In fact, the only difference between
the two assays was the identification of an additional
CYP2D6*5 gene deletion with our multiplex longer-PCR
method. Therefore, this assay is reliable for CYP2D6 geno-
typing dependent upon the polymorphisms listed.
Limitations
This method should be validated in an additional cohort
with known genotypes to ensure concordance with other
haplotype designations. This assay has not been vali-
dated to determine more than three CNVs because the
control samples did not contain subjects with more than
three. However, more than three CNVs of the identified
SNVs are universally considered UMs. If additional
CNVs of SNVs with associated lower activity scores are
found, this may become important for haplotype distinc-
tion, depending upon the genotype at the second loci.
Additional SNVs with altered predicted enzyme activity
will not be captured unless the additional primers are
added to the reaction pool. This flexibility of the method
is an advantage though the assay is limited by 10 SNVs
per pool and identification of allele duplications requires
samples to be tested in batches in order to establish ref-
erence data. Oversaturation of the assay with additional
primers in each pool may lead inconsistent detection of
SNVs. Therefore, significantly increasing the number of
SNVs identified will require larger volumes of DNA.
With the presented assay, less than 60 ng of DNA was
necessary to genotype 10 SNVs in these two genes in
each sample.
Discussion
We have demonstrated that the SNaPshot method of
genotyping CYP2D6 and ADRB1 is reliable and efficient
Table 7 ADRB1 genotype
ADRB1 haplotype Number of subjects Frequencies (%) Expected metoprolol clinical effect
49Ser389Arg/49Ser389Arg 30 25.2 Threefold greater diastolic blood pressure reduction [7, 12]
49Ser389Arg/49Gly389Arg 8 6.7 Good responder [12]
49Ser389Gly/49Gly389Arg 22 18.5 Non-responders [7, 12]
49Ser389Gly/49Ser389Gly 16 13.4 Non-responders [7, 12]
49Ser389Gly/49Gly389Gly 2 1.7 Unknown, designated good responders by prior investigators [7, 12]
49Ser389Gly/49Ser389Arg 36 30.3 Good responder [12]
49Gly389Arg/49Gly389Arg 5 4.2 Unknown, designated good responders by prior investigators [7, 12]
Table 8 CYP2D6 Allele frequencies















*41 18 7.6 %
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for rapidly identifying numerous SNVs. We demonstrate
concordance with known reference standards using this
method that requires no enzymatic digestion and can be
performed at high volumes. The only difference was an
additional identification of a CYP2D6*5 gene deletion
not identified by the Taqman method. Less than 60-ng
genomic DNA was used for each sample in our assay.
The assay is flexible; it would be easy to add additional
primers to cover more CYP2D6 SNVs should this be
necessary. This customizable assay has advantages given
the speed of discovery of CYP SNV identification. As
demonstrated by the success with CYP2D6, the multiplex
SNaPshot method can be used for designing genotype as-
says for complex genotyping circumstances rapidly and
inexpensively.
This method allows genotyping patients for two genes
at only $40 per sample compared to commercially
available microarray assays that cost in excess of $500
per sample. While the assay is limited by 10 SNVs per
pool, this provided flexibility of the assay to add
additional SNVs should they be clinically important.
Additional SNVs would require additional DNA, but
only 30 ng is required per pool allowing for significant
up-scaling of the assay. This method is well suited for
pharmacogenes with well-established clinical associa-
tions and a finite number of SNVs.
Subjects in our cohort had predicted phenotype fre-
quencies similar to European populations.
Genotypes for CYP2D6 and ADRB1 demonstrate that
25 % may have a gene-gene interaction affecting their
metoprolol therapy. Results in our cohort demonstrate a
non-responder haplotype in 31.9 % of subjects. Liu et al.
demonstrated a non-responder phenotype based upon
these same haplotypes in 45.9 % of subjects in that trial
[18]. Variability in ethnic proportions may explain this
discrepancy though the frequencies are similar. These
genes do not co-segregate, requiring knowledge of both
genotypes to determine this interaction potential. Paired
with clinical outcomes, these gene-gene interactions can
be further clarified as the cohort matures. Overall, the
multiplex SNaPshot represents a valuable tool for
systems biology studies in need of flexible genotyping
methods.
Conclusion
Our multiplex SNaPshot protocol allows for specific and
accurate detection of CYP2D6 and ADRB1 genotypes.
This platform is flexible, simple, efficient, and suited for
high throughput.
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Table 9 Genotypes, activity score and predicted phenotypes for samples with gene duplications
Genotype (xN)
before revision




Activity score Predicted phenotype
after revision
*1/*2 3 UM *1/*2xN 3 UM
*4/*41 0.5–1.0 IM OR EM *4xN/*41 0.5 IM
*1/*2 3 UM *1xN/*2 3 UM
*1/*1 3 UM *1/*1xNa 3 UM
*1/*4 1.0–2.0 EM *1/*4xN 1 EM
*4/*5 0 PM *4xN/*5 0 PM
*2/*2 3 UM *2/*2xNa 3 UM
*2/*17 2.0–2.5 UM OR EM *2/*17xN 2 EM
*4/*10 0.5–1.0 IM *4xN/*10b 0.5 IM
*1/*2 3 UM *1xN/*2 3 UM
*2/*17 2.0–2.5 UM OR EM *2/*17xN 2 EM
*4/*5 0 PM *4xN/*5 0 PM
*2/*12 1.0–2.0 EM *2xN/*12 2 EM
aThe number of duplication alleles is far less than single-copy alleles. We assumed the subject was heterozygous for a single-copy allele and the
duplicated/multiplicated allele
bNo reference
*4 had a higher distribution or copy number in comparison with *10
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